Ceftazidime/avibactam regimens and outcomes
Part of Infections clinical trials.
This trial compares different ways of giving the antibiotic ceftazidime/avibactam to see which works best. It is for people with infections caused by a type of bacteria that is hard to treat (called multidrug-resistant) but still responds to this medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Infected with a type of hard-to-treat bacteria that is sensitive to ceftazidime/avibactam
- Must have received ceftazidime/avibactam through an IV (into the vein)
- Not be allergic to ceftazidime or avibactam
- Have a blood sample available for testing
- Not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the antibiotic ceftazidime-avibactam continuously or intermittently works better for ICU patients with severe infections caused by drug-resistant bacteria. The goal is to see which method improves outcomes.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This trial looks at how well two antibiotics, ceftazidime-avibactam and fosfomycin, work together to treat infections caused by highly resistant bacteria called CRE. It may help find the best way to use these medicines.
This study looks at how well an antibiotic called ceftazidime-avibactam (CAZ-AVI) works in people with blood cancers or those who have had a stem cell transplant. It aims to find the right dose and see if the bacteria become resistant.
This study tests whether combining two antibiotics (ceftazidime and fosfomycin) works better than ceftazidime alone for hospitalized adults with serious bacterial infections. If you have a severe infection thought to be caused by Gram-negative bacteria, this trial may offer a new treatment option.
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
Hear when a new Anti-Infective Agent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.